Piper Jaffray Starts Coverage On Adverum Biotechnologies (ADVM) with $12.0 Target; Ladder Capital (LADR) Sentiment Is 1.17

February 15, 2018 - By Linda Rogers

Among 3 analysts covering Adverum Biotec… (ADVM), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Adverum Biotec… has $6.0 highest and $3.5 lowest target. $4.75’s average target is -26.92% below currents $6.5 stock price. Adverum Biotec… had 4 analyst reports since June 8, 2016 according to SRatingsIntel. The stock of Adverum Biotechnologies, Inc. (NASDAQ:ADVM) earned “Buy” rating by Raymond James on Thursday, October 12. Chardan Capital Markets downgraded Adverum Biotechnologies, Inc. (NASDAQ:ADVM) rating on Wednesday, June 8. Chardan Capital Markets has “Neutral” rating and $5 target.

Ladder Capital Corp operates as a real estate investment trust in the United States. The company has market cap of $1.62 billion. The firm operates through three divisions: Loans, Securities, and Real Estate. It has a 13.54 P/E ratio. The Loans segment originates conduit first mortgage loans that are secured by cash-flowing commercial real estate; and originates and invests in balance sheet first mortgage loans secured by commercial real estate properties that are undergoing transition, including lease-up, sell-out, and renovation or repositioning.

Adverum Biotechnologies, Inc., a gene therapy company, discovers and develops novel medicines for patients suffering from rare diseases or diseases of eye. The company has market cap of $340.64 million. The firm has a pipeline that includes product candidates to treat wet age-related macular degeneration , alpha 1 antitrypsin deficiency (A1AT), and hereditary angioedema. It currently has negative earnings. The Company’s lead gene therapy programs include ADVM-022 and ADVM-032, which are in the preclinical development of new anti-VEGF gene therapy candidates for wAMD diseases; and ADVM-043, which is in patient enrollment in a phase 1/2 trial for the treatment of A1AT.

The stock decreased 5.80% or $0.4 during the last trading session, reaching $6.5. About 1.25M shares traded or 16.92% up from the average. Adverum Biotechnologies, Inc. (ADVM) has declined 30.48% since February 15, 2017 and is downtrending. It has underperformed by 47.18% the S&P500.

Analysts await Adverum Biotechnologies, Inc. (NASDAQ:ADVM) to report earnings on March, 5. They expect $-0.35 earnings per share, down 29.63% or $0.08 from last year’s $-0.27 per share. After $-0.32 actual earnings per share reported by Adverum Biotechnologies, Inc. for the previous quarter, Wall Street now forecasts 9.37% negative EPS growth.

Analysts await Ladder Capital Corp (NYSE:LADR) to report earnings on February, 22. They expect $0.35 EPS, up 9.37% or $0.03 from last year’s $0.32 per share. LADR’s profit will be $38.77M for 10.41 P/E if the $0.35 EPS becomes a reality. After $0.35 actual EPS reported by Ladder Capital Corp for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

Glenhill Advisors Llc holds 2.6% of its portfolio in Ladder Capital Corp for 2.32 million shares. Barnett & Company Inc. owns 153,650 shares or 1.07% of their US portfolio. Moreover, Her Majesty The Queen In Right Of The Province Of Alberta As Represented By Alberta Investment Management Corp has 0.93% invested in the company for 7.23 million shares. The Pennsylvania-based Hamilton Lane Advisors Llc has invested 0.91% in the stock. Yorktown Management & Research Co Inc, a Virginia-based fund reported 250,000 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Linda Rogers

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: